FDA Requires Closer Watch On Clozapine Patients For Neutropenia Blood Disorder
SILVER SPRING, Md. — The Food and Drug Administration on Sept. 16 said it is requiring closer monitoring of patients taking the atypical antipsychotic drug clozapine (brand name Clozaril) due to...To view the full article, register now.
Already a subscriber? Click here to view full article